RxDoctor Payments Data

Muhammad Rafique

Cardiovascular Disease · Jonesboro, ARNPI 1568823912

Payments from drug & device makers

$855in general payments, 2019–2025

Across 26 payments — averaging $32.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$149
  • Livanova USA, Inc.$132
  • Boston Scientific$115
  • AstraZeneca$101
  • Abiomed$98
  • Novartis$43
  • plus $218 from 10 others

What the payments were for

  • Food & beverage$855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$855 in reported general payments places this provider in the 20th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$192,896
Medicare patients
2,433
Services billed
5,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$76,542
EntrestoSacubitril/Valsartan37$28,874
Repatha SureclickEvolocumab21$18,863
JardianceEmpagliflozin18$14,352
Praluent PenAlirocumab14$13,245
Metoprolol Succinate225$2,253
Ezetimibe81$2,084
Atorvastatin Calcium266$1,861
Ranolazine ErRanolazine15$1,388
Nitroglycerin104$951
Rosuvastatin Calcium51$603
Amlodipine Besylate99$550
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$461
Amiodarone Hcl38$400
ClopidogrelClopidogrel Bisulfate50$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$76,542104 claims
NovartisEntresto$43$28,87437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →